

Cross- Sectional

()

()

(stage)

() NYHA

()

(NT-Pro BNP ELISA, Biomedica Crop, Bratislava, - Slovakia)

B

BNP

(FEV1<1 Litr)

()

ARDS (GFR< 60)

NT-Pro BNP

(LVEF)

NT- Pro BNP

NYHA

(stage)

NT-Pro BNP

SPSS Version 13

% (CI)

class IV (/) class III
 (/) (LVEF) (/) (/)
 (/) % / ±
 (/) (/)
 NT-Pro BNP () ()
 / ± / (stage)
 CI = () (stage A) A :
 (/) (stage B) B ()
 (/) (stage C) C
 (P < /) (/) (stage D) D
 class I :
 () class II (/)

NT-Pro BNP

		NT-Pro BNP	
		Pg/ mL	
C.I = %			
P < /	±	(N =)	:
	±	(N =)	
P < /	-	±	N =
		±	N =
P < /	±	(N =)	:
	±	(N =)	
P < /	±	(N =)	:
	±	(N =)	
P < /	±	(N =)	:
	±	(N =)	

NT- Pro BNP

Stage

NT-Pro BNP

LVEF

LVEF

Stage

D Stage A

. P < /

. P < /

NT-Pro BNP

NT-Pro BNP

(Stage)

LVEF

% CI = %	Pg/ mL	NT- Pro BNP	
		LVEF	
	±		
	±		
	±		

% CI = %	Pg/ mL	NT-Pro	
		BNP Stage	
/ /	/ ± /	(N =) A	
/ /	/ ± /	(N =) B	
/ - /	/ ± /	(N =) C	
/ - /	/ ± /	(N =) D	

NT-Pro BNP

NYHA Class

Class

Class I

Class IV

(P < /).

NT-Pro BNP

NYHA Class

% CI = %	Pg/mL	NT-Pro BNP	
		NYHA Class	
/ /	/ ± /	(N =) I	
/ /	/ ± /	(N =) II	
/ /	/ ± /	(N =) III	
/ /	/ ± /	(N =) IV	

.()

NT-Pro BNP

NT-Pro BNP
(stage)

NYHA class
(LVEF)

NYHA class III , IV (Stage C,D)

Betten court , Dao , Jacop

NT- Pro BNP

NT- Pro BNP

Bay .() .() .

NT- Pro BNP

Hunt

ANP BNP

NT- Pro BNP

(LVEF) (multivariate model)

NT- Pro BNP BNP ()

NT- Pro BNP

() BNP

NT-Pro BNP

BNP

NT-Pro BNP

()

BNP

NYHA

(LVEF)


BNP

NT-Pro BNP

()

Jacob

NT-Pro BNP



REFERENCES

1. Braunwald E. Heart failure and cor pulmonale. in: Kasper DL, Braunwald E, Fauci AS, editors Harrison's principle of internal medicine, 16th ed. New York: MC Graw- Hill Ind; 2005: 1367- 77.
2. Joung B, Park B, Kim DS, Hong BK, Kim DY, Cho YH, et al. B-type natriuretic peptide predicts clinical presentations and ventricular over loading in patients with heart failure. Yonsei Med J 2003; 44(4): 623-34.
3. Troughton RW, Christopher F. Treatment of heart failure guided by plasma amino terminal brain natriuretic peptide (N- BNP) concentrations. Lancet 2000; 355: 1126- 30.
4. Maisel, AS, Krishnaswamy P, Nowak RM. Rapid measurement of B- type natriuretic peptide in the emergency diagnosis of heart failure. N Eng J med 2002; 347: 161-7.
5. Jose JV, Gupta SN, Selvakuma D. Utility of N- terminal pro- brain natriuretic peptide for the diagnosis of heart failure. Indian heart J 2003; 55: 35-9.
6. Hunt PJ, Richards AM, Nichollas MG. Immunoreactive amino terminal Pro- BNP: a new marker of cardiac impairment. Clin Endocrinol (OXF) 1997; 47: 287.
7. Dao Q, Krishnaswamy P, Kazanegra R. Utility of B- Type natriuretic peptide in the diagnosis of congestive heart failure in an urgent- care setting. J Am Coll Cardiol 2001; 37: 379- 85.
8. Bettencourt P, Ferreira A, Dias P. Evaluation of brain natriuretic peptide in the diagnosis of heart failure. Cardiology 2000; 93: 19- 25.
9. Richards AM, Nichollas MG, Yandle TG, Frampton C, Espiner EA, Turner TG, et al. Plasma N-terminal Pro- BNP and adreno medullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infraction. Circulation 1998; 97: 1921-9.
10. Bay M, Kirk V, Parner J, Hassager C, Nielsen H, Krogsgaard K, et al. NT- Pro BNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart 2003; 89: 150-4.

-
11. [No Author Listed]. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J med 1991; 325(5): 293-302.
 12. Murdoch DR, Mc Donough TA, Byrne J. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am heart J 1998; 138: 1126- 32.